Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

NCT Number	NCT07190222
Lead Sponsor	Sanofi
Conditions	Chronic Obstructive Pulmonary Disease
Enrollment	942 participants
Start Date	2025-09-17
Primary Completion	2029-11-27 (estimated)
Study Completion	2030-01-22 (estimated)
Updated on ClinicalTrials.gov	2026-06-15